The third batch of national drug procurement with volume will be opened in Shanghai on August 20
Shanghai Sunshine Pharmaceutical Procurement Network released the third batch of documents related to the procurement of national drugs in quantity. The documents show that 56 varieties are involved in total, and the bid will be opened in Shanghai on August 20, 2020. In general, the centralized purchase rule is close to the second batch of purchase documents with quantity. So as to further reduce the drug burden of the masses.
20
2022
/
09
On May 24, the Hunan Provincial Health Commission, in conjunction with the Hunan Provincial Administration of Traditional Chinese Medicine and the Hunan Provincial Drug Administration, issued the Notice on Printing and Distributing the Hunan Provincial Prescription Circulation and Supervision Work Plan (Trial) (hereinafter referred to as the Trial Plan), proposing to establish a unified prescription circulation and supervision platform across the province, realize the circulation of prescription data of various medical institutions, and carry out the extension of hospital prescriptions, intelligent online review, chronic disease continuation Rational drug use monitoring.
20
2022
/
09
According to the State Medical Insurance Bureau, on May 19, Yu Yanhong, secretary of the Party Leadership Group of the State Administration of Traditional Chinese Medicine, and Li Tao, member of the Party Leadership Group and deputy director of the State Medical Insurance Bureau, led a team to the Guang'anmen Hospital of the Chinese Academy of Traditional Chinese Medicine to carry out a special research on "medical insurance supports the development of traditional Chinese medicine".
20
2022
/
09
The Chinese Academy of Sciences found that NAD+ and NMN may be able to treat COVID-19
As we all know, patients with severe COVID-19 suffer from severe respiratory distress, and many people lose their lives as a result, it is urgent to find effective ways to deal with COVID-19. Although a vaccine with high protective efficacy has been developed, the rapid mutation of COVID-19 has created great uncertainty in the COVID-19 pandemic, which has made the development of COVID-19 treatment a priority option.
20
2022
/
09
Pannacean (Henan) Medicine Science Technologies, Ltd.
Address: Henan Pilot Free Trade Zone Zhengzhou Area (Jingkai) Hanghai Road Jingkai 2nd Street Hanghai East Road No. 1291
Pannacean (Henan) Medicine Science Technologies, Ltd.
Address: Henan Pilot Free Trade Zone Zhengzhou Area (Jingkai) Hanghai Road Jingkai 2nd Street Hanghai East Road No. 1291
Mail：haifeng.zhang@pannacean.com
Tel:0371-55159968